Isolation and characterization of tumorspheres from a recurrent pineoblastoma patient: Feasibility of a patient-derived xenograft

Jiyong Kwak, Jin Kyoung Shim, Dong Seok Kim, Ji Hyun Lee, Junjeong Choi, Junseong Park, Kyoung Jin Shin, SeHoon Kim, Pilnam Kim, yongmin Huh, Eui Hyun Kim, Jong Hee Chang, Sun Ho Kim, Seok-Gu Kang

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

The existence of tumorspheres (TSs) might confer treatment resistance to pineoblastoma (PB). The existence of PB TSs with cellular immortalization potential has not yet been reported. We developed a procedure for isolating TSs from recurrent PB (rPB) and tested whether their properties made them suitable for use as a patient-derived xenograft (PDX). Immunocytochemical staining, RT-PCR and quantitative real-time PCR showed that, among stemness proteins, CD133, musashi and podoplanin were expressed at elevated levels in rPB TSs, but nestin was not. rPB TSs cultured under neuro-glial differentiation conditions expressed TUBB3, but not GFAP, MBP or NeuN. Unlike glioblastoma TSs, rPB TSs showed no clear evidence of invasion in 3D invasion assay or increased expression of genes associated with epithelialmesenchymal transition. An orthotopic xenograft showed that tumor xenografts replicated the histopathological features of the patient tumor and expressed similar genome profiles, as determined by short tandem repeat genotyping. These data demonstrate the isolation and the characterization of rPB TSs for the first time. Using an orthotopic xenograft, we showed that rPB TSs could replicate the patient tumor, demonstrating their potential as a PDX for precision medicine.

Original languageEnglish
Pages (from-to)569-578
Number of pages10
JournalInternational journal of oncology
Volume49
Issue number2
DOIs
Publication statusPublished - 2016 Aug 1

Fingerprint

Pinealoma
Heterografts
Nestin
Neoplasms
Precision Medicine
Glioblastoma
Neuroglia
Microsatellite Repeats
Real-Time Polymerase Chain Reaction
Genome
Staining and Labeling
Gene Expression
Polymerase Chain Reaction
Proteins

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Kwak, Jiyong ; Shim, Jin Kyoung ; Kim, Dong Seok ; Lee, Ji Hyun ; Choi, Junjeong ; Park, Junseong ; Shin, Kyoung Jin ; Kim, SeHoon ; Kim, Pilnam ; Huh, yongmin ; Kim, Eui Hyun ; Chang, Jong Hee ; Kim, Sun Ho ; Kang, Seok-Gu. / Isolation and characterization of tumorspheres from a recurrent pineoblastoma patient : Feasibility of a patient-derived xenograft. In: International journal of oncology. 2016 ; Vol. 49, No. 2. pp. 569-578.
@article{f1e88c7b2fdf4a799ae8da92f236d52e,
title = "Isolation and characterization of tumorspheres from a recurrent pineoblastoma patient: Feasibility of a patient-derived xenograft",
abstract = "The existence of tumorspheres (TSs) might confer treatment resistance to pineoblastoma (PB). The existence of PB TSs with cellular immortalization potential has not yet been reported. We developed a procedure for isolating TSs from recurrent PB (rPB) and tested whether their properties made them suitable for use as a patient-derived xenograft (PDX). Immunocytochemical staining, RT-PCR and quantitative real-time PCR showed that, among stemness proteins, CD133, musashi and podoplanin were expressed at elevated levels in rPB TSs, but nestin was not. rPB TSs cultured under neuro-glial differentiation conditions expressed TUBB3, but not GFAP, MBP or NeuN. Unlike glioblastoma TSs, rPB TSs showed no clear evidence of invasion in 3D invasion assay or increased expression of genes associated with epithelialmesenchymal transition. An orthotopic xenograft showed that tumor xenografts replicated the histopathological features of the patient tumor and expressed similar genome profiles, as determined by short tandem repeat genotyping. These data demonstrate the isolation and the characterization of rPB TSs for the first time. Using an orthotopic xenograft, we showed that rPB TSs could replicate the patient tumor, demonstrating their potential as a PDX for precision medicine.",
author = "Jiyong Kwak and Shim, {Jin Kyoung} and Kim, {Dong Seok} and Lee, {Ji Hyun} and Junjeong Choi and Junseong Park and Shin, {Kyoung Jin} and SeHoon Kim and Pilnam Kim and yongmin Huh and Kim, {Eui Hyun} and Chang, {Jong Hee} and Kim, {Sun Ho} and Seok-Gu Kang",
year = "2016",
month = "8",
day = "1",
doi = "10.3892/ijo.2016.3554",
language = "English",
volume = "49",
pages = "569--578",
journal = "International Journal of Oncology",
issn = "1019-6439",
publisher = "Spandidos Publications",
number = "2",

}

Isolation and characterization of tumorspheres from a recurrent pineoblastoma patient : Feasibility of a patient-derived xenograft. / Kwak, Jiyong; Shim, Jin Kyoung; Kim, Dong Seok; Lee, Ji Hyun; Choi, Junjeong; Park, Junseong; Shin, Kyoung Jin; Kim, SeHoon; Kim, Pilnam; Huh, yongmin; Kim, Eui Hyun; Chang, Jong Hee; Kim, Sun Ho; Kang, Seok-Gu.

In: International journal of oncology, Vol. 49, No. 2, 01.08.2016, p. 569-578.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Isolation and characterization of tumorspheres from a recurrent pineoblastoma patient

T2 - Feasibility of a patient-derived xenograft

AU - Kwak, Jiyong

AU - Shim, Jin Kyoung

AU - Kim, Dong Seok

AU - Lee, Ji Hyun

AU - Choi, Junjeong

AU - Park, Junseong

AU - Shin, Kyoung Jin

AU - Kim, SeHoon

AU - Kim, Pilnam

AU - Huh, yongmin

AU - Kim, Eui Hyun

AU - Chang, Jong Hee

AU - Kim, Sun Ho

AU - Kang, Seok-Gu

PY - 2016/8/1

Y1 - 2016/8/1

N2 - The existence of tumorspheres (TSs) might confer treatment resistance to pineoblastoma (PB). The existence of PB TSs with cellular immortalization potential has not yet been reported. We developed a procedure for isolating TSs from recurrent PB (rPB) and tested whether their properties made them suitable for use as a patient-derived xenograft (PDX). Immunocytochemical staining, RT-PCR and quantitative real-time PCR showed that, among stemness proteins, CD133, musashi and podoplanin were expressed at elevated levels in rPB TSs, but nestin was not. rPB TSs cultured under neuro-glial differentiation conditions expressed TUBB3, but not GFAP, MBP or NeuN. Unlike glioblastoma TSs, rPB TSs showed no clear evidence of invasion in 3D invasion assay or increased expression of genes associated with epithelialmesenchymal transition. An orthotopic xenograft showed that tumor xenografts replicated the histopathological features of the patient tumor and expressed similar genome profiles, as determined by short tandem repeat genotyping. These data demonstrate the isolation and the characterization of rPB TSs for the first time. Using an orthotopic xenograft, we showed that rPB TSs could replicate the patient tumor, demonstrating their potential as a PDX for precision medicine.

AB - The existence of tumorspheres (TSs) might confer treatment resistance to pineoblastoma (PB). The existence of PB TSs with cellular immortalization potential has not yet been reported. We developed a procedure for isolating TSs from recurrent PB (rPB) and tested whether their properties made them suitable for use as a patient-derived xenograft (PDX). Immunocytochemical staining, RT-PCR and quantitative real-time PCR showed that, among stemness proteins, CD133, musashi and podoplanin were expressed at elevated levels in rPB TSs, but nestin was not. rPB TSs cultured under neuro-glial differentiation conditions expressed TUBB3, but not GFAP, MBP or NeuN. Unlike glioblastoma TSs, rPB TSs showed no clear evidence of invasion in 3D invasion assay or increased expression of genes associated with epithelialmesenchymal transition. An orthotopic xenograft showed that tumor xenografts replicated the histopathological features of the patient tumor and expressed similar genome profiles, as determined by short tandem repeat genotyping. These data demonstrate the isolation and the characterization of rPB TSs for the first time. Using an orthotopic xenograft, we showed that rPB TSs could replicate the patient tumor, demonstrating their potential as a PDX for precision medicine.

UR - http://www.scopus.com/inward/record.url?scp=84978435038&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84978435038&partnerID=8YFLogxK

U2 - 10.3892/ijo.2016.3554

DO - 10.3892/ijo.2016.3554

M3 - Article

C2 - 27277549

AN - SCOPUS:84978435038

VL - 49

SP - 569

EP - 578

JO - International Journal of Oncology

JF - International Journal of Oncology

SN - 1019-6439

IS - 2

ER -